Related content

Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate

By Simonelli Christine   Burke M. Susan  

Current Medical Research and Opinion, Vol. 22, Iss. 6, 2006-06 ,pp. : 1101-1108

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

By Recker R.   Weinstein R.   Chesnut C.   Schimmer R.   Mahoney P.   Hughes C.   Bonvoisin B.   Meunier P.  

Osteoporosis International, Vol. 15, Iss. 3, 2004-03 ,pp. : 231-237

Springer Publishing Company

Access to resources Recommend Favorite

Long dosing intervals in the treatment of postmenopausal osteoporosis

By Lewiecki E. Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2617-2625

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

By Harris Steven T.   Blumentals William A.   Miller Paul D.  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 237-245

Informa Healthcare

Access to resources Recommend Favorite